Researcher

Yang Han

Shanghai Jiao Tong University

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 9, 2026 · JOURNAL ARTICLE

Discovery of tepotinib as a novel LY75-targeting small-molecule inhibitor with anti-tumor activity in ovarian cancer via virtual screening

Journal of Ovarian Research

Preclinical discovery study using virtual screening and in vitro/xenograft models without clinical data; identifies a candidate compound but requires clinical validation.

PreliminaryWei Xia Lung Cancer Treatments and Mutations Ovarian Cancer Diagnosis and Treatment

Reported

IC₅₀ (SKOV3 cells)16.31 µM

IC₅₀ (OVCAR-8 cells)18.91 µM

Kinetic K_D (tepotinib–LY75 bindi…2.52 µM

AUG 26, 2026 · JOURNAL ARTICLE

Comprehensive evaluation of metagenomic next‐generation sequencing for pathogen identification in patients with suspected infection: Establishment of a standardized validation workflow

Open Research

Rigorous multi-phase validation study with analytical benchmarking, large retrospective cohort comparison, and prospective clinical impact assessment, demonstrating superior sensitivity and turnaround time versus culture; not practice-changing alone because it remains positioned as adjunct to conventional testing.

Strong EvidenceLin Wang Chunyan He Wen Shu

Reported

Qualitative concordance100%

Limit of detection (minimum)10.0 copies/mL

Limit of detection (maximum)269.1 copies/mL